Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities
Marie‐Laure Ozoux(Sanofi (France)), Philip Janiak(Hôpital Lariboisière), J.M. Altenburger(Sanofi (France)), Fabrice Barbe(Sanofi (France)), Bruno Poirier(Sanofi (France)), Jean‐Pierre Bidouard(Hôpital Lariboisière), Philippe Beauverger(Sanofi (France)), Véronique Briand(Sanofi (France)), Jean‐Michel Guillon(Sanofi (France)), Paul Schaeffer(Universidad La Salle), Frédéric Petit(Sanofi (France)), Michel Pelat(Sanofi (France))
Cited by 16
Related Papers
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|943
PGC-1α Coactivates PDK4 Gene Expression via the Orphan Nuclear Receptor ERRα: a Mechanism for Transcriptional Control of Muscle Glucose Metabolism
|Molecular and Cellular Biology|2005|355
The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways
|The Journal of Experimental Medicine|2002|349
Transcriptional coactivators PGC-1α and PGC-lβ control overlapping programs required for perinatal maturation of the heart
|Genes & Development|2008|325
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy
|Journal of Clinical Investigation|2005|260